| Twist Bioscience to Present at William Blair 45th Annual Growth Stock Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor. |
businesswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units (“RSUs”) and up to 19,379 performance stock units (“PSUs”), to 36 recently hired individuals, in each case as an. |
businesswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience and Ginkgo Bioworks Revise Collaboration |
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agr. |
businesswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience: Expansion Efforts Continue To Face Challenges |
Twist Bioscience reported solid results in Q2, but management's downbeat tone on the earnings call suggest there are challenges ahead. Twist has also spun-out its data storage business, which will help to reduce cash burn. The transaction attributes a fairly modest valuation to the business, though. This comes after the recent struggles of the biopharma business and a royalty sale, which suggests the biopharma business hasn't created much value so far. |
seekingalpha.com |
2025-05-07 06:18:26 |
Czytaj oryginał (ang.) |
| Twist Bioscience Corporation (TWST) Q2 2025 Earnings Call Transcript |
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2025 Earnings Conference Call April 5, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Matthew Sykes - Goldman Sachs Subbu Nambi - Guggenheim Securities Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank Thomas Peterson - Baird Brendan Smith - TD Cowen Operator Good day. Thank you for standing by. |
seekingalpha.com |
2025-05-05 15:41:25 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates |
Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago. |
zacks.com |
2025-05-05 13:25:32 |
Czytaj oryginał (ang.) |
| Twist Bioscience Announces Fiscal 2025 Second Quarter Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report a. |
businesswire.com |
2025-05-05 11:15:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience Spins Out DNA Data Storage as Independent Company |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that the company has spun out its DNA data storage technology application as an independent company, named Atlas Data Storage (“Atlas”). “There are many applications of synthetic DNA with the potential to have an incredible impact on the world. With this spin out, both Twist and Atlas are. |
businesswire.com |
2025-05-05 11:10:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers |
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, Twist's stock has experienced sharp declines post-earnings on underwhelming financials. 2025 guidance shows ~20% revenue growth, but the market remains skeptical of Twist's ability to achieve profitability, leading to my downgrade from "Buy" to "Hold". |
seekingalpha.com |
2025-05-01 16:05:06 |
Czytaj oryginał (ang.) |
| Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System. |
businesswire.com |
2025-04-24 12:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics |
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate the adoption of NGS workflows in agricultural genomics (agrigenomics) by offering Twist's FlexPrep™ Ultra-High Throughput (UHT) Library Preparation Kit with Curio's bioinformatics software. |
businesswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Promising Genomics & Synthetic Biology Stocks to Consider in 2025 |
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG. |
zacks.com |
2025-03-28 12:41:17 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last? |
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-03-12 15:15:31 |
Czytaj oryginał (ang.) |
| Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. “At Twist, we recognize the increasing challenge within colleges, universities and research ins. |
businesswire.com |
2025-03-11 09:30:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know |
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-06 15:00:24 |
Czytaj oryginał (ang.) |
| Cathie Wood dumped Palantir to buy these biotech stocks |
Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure. |
finbold.com |
2025-02-06 10:42:34 |
Czytaj oryginał (ang.) |
| Twist Bioscience: Valuation Is Weighing On The Stock |
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future. |
seekingalpha.com |
2025-02-06 01:30:03 |
Czytaj oryginał (ang.) |
| Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript |
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by. |
seekingalpha.com |
2025-02-03 12:55:27 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates |
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. |
zacks.com |
2025-02-03 11:25:15 |
Czytaj oryginał (ang.) |
| Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report. |
businesswire.com |
2025-02-03 09:15:00 |
Czytaj oryginał (ang.) |
| Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research |
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). |
globenewswire.com |
2025-01-23 12:35:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy |
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-27 15:00:31 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains? |
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-12-23 11:51:34 |
Czytaj oryginał (ang.) |
| Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California. The presentation will be webcast live and can be accessed by visiting the “I. |
businesswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-12-16 12:57:20 |
Czytaj oryginał (ang.) |
| Twist Bioscience: Path To Profitability Beginning To Take Shape |
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and royalties to XOMA for a small amount. Twist's margins continue to improve, and the company now appears to be on a path to cash flow breakeven over the next few years. |
seekingalpha.com |
2024-11-29 11:55:53 |
Czytaj oryginał (ang.) |
| Twist Bioscience: A Post-Earnings Assessment |
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid balance sheet and north of $1.2 billion in net loss carry forwards. |
seekingalpha.com |
2024-11-18 17:16:33 |
Czytaj oryginał (ang.) |
| Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps |
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents. |
benzinga.com |
2024-11-18 14:17:34 |
Czytaj oryginał (ang.) |
| Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript |
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Founder Adam Laponis - CFO Patrick Finn - President and COO Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Luke Sergott - Barclays Matt Larew - William Blair Puneet Souda - Leerink Partners Tom Peterson - Baird Chad Wiatrowski - TD Cowen Thomas DeBourcy - Nephron Research Rachel Vatnsdal - JPMorgan Operator Welcome to Twist Bioscience's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-18 13:31:36 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates |
Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago. |
zacks.com |
2024-11-18 11:25:29 |
Czytaj oryginał (ang.) |
| Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and. |
businesswire.com |
2024-11-18 09:15:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy' |
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation multiples now appear more reasonable, making it a compelling buy for new investors, with a long cash runway and potential self-sustainability by 2025-2026. The company has improved its gross margins and reduced EBIT margins, signaling rapid margin improvement and benefiting from economies of scale. |
seekingalpha.com |
2024-11-08 07:14:19 |
Czytaj oryginał (ang.) |
| Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics). |
businesswire.com |
2024-10-30 10:00:00 |
Czytaj oryginał (ang.) |
| Twist Bioscience to Present at Baird Global Healthcare Conference 2024 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “I. |
businesswire.com |
2024-08-27 12:00:00 |
Czytaj oryginał (ang.) |
| 3 Healthcare AI Stocks Positioned for Potential Breakthroughs |
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen. |
investorplace.com |
2024-08-07 10:47:00 |
Czytaj oryginał (ang.) |
| The 3 Best Med Tech Stocks to Buy Now |
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments. |
investorplace.com |
2024-08-05 15:20:44 |
Czytaj oryginał (ang.) |
| Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade) |
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market. |
seekingalpha.com |
2024-08-04 12:50:17 |
Czytaj oryginał (ang.) |
| Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript |
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Tom Peterson - Baird Thomas DeBourcy - Nephron Research Operator Good day, and thank you for standing by. Welcome to Twist Bioscience Fiscal 2024 Third Quarter Financial Results Conference Call. |
seekingalpha.com |
2024-08-02 18:37:05 |
Czytaj oryginał (ang.) |
| Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates |
Twist Bioscience (TWST) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $1.01 per share a year ago. |
zacks.com |
2024-08-02 13:40:58 |
Czytaj oryginał (ang.) |
| Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We once again surpassed our revenue guidance, ending the quarter with $81.5 million in revenue, and exceeded our targets for both cash burn and gross margin," said Emily M. |
businesswire.com |
2024-08-02 11:30:00 |
Czytaj oryginał (ang.) |
| Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2024-07-30 13:50:50 |
Czytaj oryginał (ang.) |